Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 316

1.

Macrolides in cystic fibrosis.

McArdle JR, Talwalkar JS.

Clin Chest Med. 2007 Jun;28(2):347-60. Review.

PMID:
17467553
2.

Macrolides in cystic fibrosis: is there a role?

Wolter JM, Seeney SL, McCormack JG.

Am J Respir Med. 2002;1(4):235-41. Review.

PMID:
14720043
3.

Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis.

Schultz MJ.

J Antimicrob Chemother. 2004 Jul;54(1):21-8. Epub 2004 Jun 9. Review.

PMID:
15190022
5.
6.

Anti-inflammatory effects of macrolides in lung disease.

Jaffé A, Bush A.

Pediatr Pulmonol. 2001 Jun;31(6):464-73. Review.

PMID:
11389580
7.
8.

Macrolide antibiotic therapy in patients with cystic fibrosis.

Schöni MH.

Swiss Med Wkly. 2003 May 31;133(21-22):297-301. Review.

PMID:
12861467
9.

Potential role of macrolide antibiotics in the management of cystic fibrosis lung disease.

Nguyen T, Louie SG, Beringer PM, Gill MA.

Curr Opin Pulm Med. 2002 Nov;8(6):521-8. Review.

PMID:
12394161
10.

Macrolides and airway inflammation in children.

Shinkai M, Rubin BK.

Paediatr Respir Rev. 2005 Sep;6(3):227-35. Review.

PMID:
16153572
11.

Regulatory effects of macrolides on bacterial virulence: potential role as quorum-sensing inhibitors.

Tateda K, Standiford TJ, Pechere JC, Yamaguchi K.

Curr Pharm Des. 2004;10(25):3055-65. Review.

PMID:
15544497
12.
13.

Suppression of Pseudomonas aeruginosa quorum-sensing systems by macrolides: a promising strategy or an oriental mystery?

Tateda K, Ishii Y, Kimura S, Horikawa M, Miyairi S, Yamaguchi K.

J Infect Chemother. 2007 Dec;13(6):357-67. Epub 2007 Dec 25. Review.

PMID:
18095083
14.

Macrolides as immunomodulatory medications for the therapy of chronic lung diseases.

López-Boado YS, Rubin BK.

Curr Opin Pharmacol. 2008 Jun;8(3):286-91. doi: 10.1016/j.coph.2008.01.010. Epub 2008 Mar 12. Review.

PMID:
18339582
15.

Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function.

Tramper-Stranders GA, Wolfs TF, Fleer A, Kimpen JL, van der Ent CK.

Pediatr Infect Dis J. 2007 Jan;26(1):8-12.

PMID:
17195698
16.

Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.

Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J.

Thorax. 2002 Mar;57(3):212-6.

17.

New and emerging therapies for pulmonary complications of cystic fibrosis.

Tonelli MR, Aitken ML.

Drugs. 2001;61(10):1379-85. Review.

PMID:
11558827
18.

Clinical implications of macrolide therapy in chronic sinopulmonary diseases.

Martinez FJ, Simon RH.

Curr Pharm Des. 2004;10(25):3095-110. Review.

PMID:
15544500
19.

Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis.

Phaff SJ, Tiddens HA, Verbrugh HA, Ott A.

J Antimicrob Chemother. 2006 Apr;57(4):741-6. Epub 2006 Feb 9.

PMID:
16469851
20.

Macrolides in the treatment of asthma and cystic fibrosis.

Ferrara G, Losi M, Franco F, Corbetta L, Fabbri LM, Richeldi L.

Respir Med. 2005 Jan;99(1):1-10. Review.

PMID:
15672842

Supplemental Content

Support Center